49 listed companies disclosed their 2022 first quarter reports, including 5 pharmaceutical companies including Keqian Bio and Chengda Pharmaceutical
Time of Update: 2022-05-10
05% year-on-year According to the performance report of Xiangsheng Medical for the first quarter of 2022, from January 1, 2022 to March 31, 2022, the company achieved an operating income of 100 million yuan, a year-on-year increase of 23.
The plasma protein fibrinogen directly interacts with nerve cells, causing brain inflammation
Time of Update: 2022-01-06
David Lomadze, Professor of Surgery, Molecular Pharmacology, and Physiology at the Morsani School of Medicine at the University of South Florida Health (USF Health), studied how changes in the blood vessels caused by neuroinflammation impair cognition, including short-term memory .
FDA opens a new era of mandatory enforcement of regenerative medicine therapy and stricter supervision is coming
Time of Update: 2021-05-10
In other warning letters during the COVID-19 pandemic, the FDA also pointed out that its risk-based enforcement approach means that regenerative medicine therapies designed to prevent or treat COVID-19 are more likely to attract the attention of CBER, including intravenous or intrathecal administration.
Yiyi Biotech submitted Ryzneuta(TM) Biological Products License Application (BLA) to the US FDA
Time of Update: 2021-04-14
Following the completion of the global phase III clinical trial of chemotherapy-induced neutropenia for breast cancer patients, Yiyi Biotech submitted the relevant BLA application to the US FDA .
Biological analogues are coming to Novartis
Time of Update: 2014-09-16
Source: e-medicine Facebook 2014-9-16 once the patent of brand chemicals expires, patients can buy low-cost generic versions, such as Lipitor and Prozac In total, generics saved the country $239 billi